Edit

CytoDyn

https://www.cytodyn.com/

Last activity: 29.02.2024

Categories: BioTechDevelopmentHumanInterestITLifeLiving

CytoDyn is a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses. The Company is developing subcutaneously delivered humanized cell-specific monoclonal antibodies (mAbs) as entry inhibitors for the treatment and prevention of Human Immunodeficiency Virus (HIV). The Company has one of the leading mAbs under development for HIV infection, PRO 140, which is a Late Stage 2 humanized mAb with demonstrated antiviral activity humans. PRO 140 blocks the HIV co-receptor CCR5, and clinical trial results thus far indicate that it does not affect the normal function of the cell. Results from Phase 1/1b and Phase 2a human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. CytoDyn intends to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV.

Likes

1.64K

Followers

4.29K

Website visits

6.3K /mo.

Mentions

Location: United States, Washington, Vancouver

Employees: 11-50

Founded date: 2002

Twitter

Facebook

Investors 1

Date	Name	Website
-	Centrecour...	centrecour...

Mentions in press and media 27

Date	Title	Description	Source
07.12.2023	CytoDyn Announces Webcast to Provide Company Update	VANCOUVER, Washington, Dec. 07, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn&q...	einpresswi...
22.11.2022	CytoDyn to Host R&D Update on Wednesday, December 7, 202...	/EIN News/ -- VANCOUVER, Washington, Nov. 22, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (&...	einpresswi...
28.10.2022	CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Du...	Company to complete and submit responses to FDA clinical hold Continues to study leronlimab in other...	globenewsw...
28.10.2022	CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Du...	/EIN News/ -- Company to complete and submit responses to FDA clinical hold Continues to study leron...	einpresswi...
19.09.2022	CytoDyn to Hold Webcast to Provide a Quarterly Company Updat...	/EIN News/ -- VANCOUVER, Washington, Sept. 19, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (...	einpresswi...
19.09.2022	CytoDyn to Hold Webcast to Provide a Quarterly Company Updat...	VANCOUVER, Washington, Sept. 19, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn&...	globenewsw...
22.06.2022	CytoDyn to Hold Webcast to Provide a Quarterly Company Updat...	VANCOUVER, Washington, June 22, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn&q...	globenewsw...
30.03.2022	CytoDyn Announces Partial Clinical Hold of HIV Program and F...	Live webcast to be held March 31 discussing announcement VANCOUVER, Washington, March 30, 2022 (GLOB...	globenewsw...
30.03.2022	CytoDyn to Hold Webcast to Provide Company Update	VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn&...	globenewsw...
27.05.2021	Lawsuit: Investors bet big on Washington firm’s potential CO...	(CytoDyn Photo via investor webcast) Investors in a biotech startup developing a COVID-19 treatment ...	geekwire.c...
23.04.2021	CYTODYN INC. CytoDyn Completes $28.5 Million Convertible No...	Company Achieves Total Financing in April of $57 Million VANCOUVER, Washington, April 22, 2021 (GLOB...	marketscre...
05.04.2021	CYTODYN INC. CytoDyn Completes $28.5 Million Convertible No...	VANCOUVER, Washington, April 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or...	marketscre...
08.03.2021	Covid-19 roundup: Merck and Ridgeback report early data...	A couple of months after scrapping its Covid-19 vaccine program, Merck has read out early da...	endpts.com...
08.03.2021	Gilead's Biktarvy build its case for long-term use with 4-...	Gilead Sciences’ daily pill Biktarvy has been one of biopharma’s great success stories, ridi...	endpts.com...
08.03.2021	Mount Sinai leasing office space for outpatient clinics...	A prominent New York City medical school has leased out office space in order to expand its med...	endpts.com...
08.03.2021	CytoDyn tries to squeeze positive news out of a failed C...	AnaptysBio shares got hammered Monday morning after the biotech conceded defeat for the first mid-st...	endpts.com...
08.03.2021	CytoDyn tries to squeeze positive news out of a failed C...	The “industry-wide review of accelerated approvals” that’s been making waves in the checkpoint field...	endpts.com...
08.03.2021	Martin Shkreli faces another lawsuit, this time from in...	The notorious “Pharma Bro” Martin Shkreli prompted national outrage in 2015 when he and th...	endpts.com...
08.03.2021	Gilead's Kite keeps adding to CAR-T Yescarta's bag of tric...	Several months after creating the first commercial CAR-T portfolio with the FDA’s nod for T...	endpts.com...
08.03.2021	Biotech IPO market looks to ramp back up as BMS partner Ik...	Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmar...	endpts.com...
08.03.2021	CytoDyn tries to squeeze positive news out of a failed C...	CytoDyn really, really wanted to put its best foot forward. So much so that, after sitting...	endpts.com...
05.03.2021	CytoDyn to Hold Webcast on March 8 to Provide Overview of CD...	VANCOUVER, Washington, March 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or...	globenewsw...
13.07.2020	CytoDyn shares slammed as BLA filing for leronlimab in H...	In a press release issued in early June announcing a BLA acknowledgment letter from the FDA...	endpts.com...
01.04.2020	Coronavirus Business Tracker: How The Private Sector Is Figh...	Alain Mérieux, founder of BioMérieux.AFP via Getty Images	forbes.com...
20.03.2020	Charles Bancroft makes quick leap from Bristol Myers exe...	Charles Bancroft → Just a few days after Bristol Myers reported that Charles Bancroft had “re...	endpts.com...
30.04.2019	Washington VC Watch: Pattern Computer, Chatbox, Joylux &...	Share Share on Facebook Share on Twitter LinkedIn Email Reprints Catch up on funding news from April...	xconomy.co...
-	A top credit-risk firm says these are the 10 biotech compani...	Credit Risk Monitor tracks the risk of bankruptcy across thousands of companies. Maksim Safaniuk/ Ge...	businessin...

CytoDyn

Investors 1

Mentions in press and media 27

Reviews 0